Guidelines for immunotherapy of antigen-specific defects with transfer factor

Area of Science:

• Immunology
• Microbiology
• Infectious Diseases

Background:

• Dialyzable leukocyte extracts (DLE) containing transfer factor (TF) have shown variable clinical effectiveness in treating diverse infectious diseases and immunodeficiencies.
• Previous challenges included inconsistent efficacy and difficulty in predicting treatment outcomes.

Observation:

• Recent advancements in assays allow for donor screening, recipient monitoring, and potency determination of DLE preparations.
• Specific DLE preparations were tested in patients with selective immunodeficiencies to Candida and Mycobacterium fortuitum.

Findings:

• New assays significantly improved the success rate of TF immunotherapy.
• Patients responded positively to specific DLE preparations, demonstrating clinical improvement and enhanced laboratory test results.
• Certain DLE preparations exhibited immunosuppressive effects in vivo, which were predictable through in vitro testing.

Implications:

• These findings suggest that optimized immunotherapy with TF, guided by new assays, can effectively treat specific immunodeficiencies.
• The ability to predict DLE preparation potency and patient response enhances therapeutic outcomes.
• Guidelines for optimal DLE therapy are proposed based on these improved predictive capabilities.